South Korea’s MFDS cleared Curocell’s Limcato (anbalcabtagene-autoleucel) as the first locally developed CAR T-cell therapy for advanced diffuse large B-cell lymphoma. The approval positions Limcato as a homegrown option in a market dominated by multinational CAR-T products. The approval is a notable regulatory milestone for South Korean cell therapy manufacturing and development, signaling progress toward greater domestic capability. For operators, it also impacts competitive dynamics and patient access as local supply ramps.